PHARMACOKINETIC AND PHARMACOGENETIC ASPECTS OF PERSONALIZED ANALGETIC THERAPY WITH FENTANIL TTS IN CLINICAL ONCOLOGY

The aim of the study was the pharmacokinetic and pharmacogenetic analysis of analgetic efficacy and safety of transdermal fentanyl for cancer patients.

Material and methods. A comprehensive search for journal articles
published between 2012 and 2017 was carried out using PubMed, Scopus, Web of Science, and E-library databases.

Results. The analysis of the data showed that pharmacokinetic and pharmacogenetic factors can influence the interindividual variability  of analgesic therapy with fentanyl TTC for cancer patients,  predetermining phenotypic differences in the efficacy and safety of  analgesia. Enforced polypharmacotherapy with the use of inducers or inhibitors of the CYP3A4 isoenzyme activity can significantly change  the effectiveness of analgesic therapy and result in undesirable side  effects of strong opioids. Contradictory data on the effect of some  single nucleotide polymorphisms of metabolic genes, transport genes and mu-opioid receptor genes dictate the necessity of further studies in this field.

Conclusion. To date, there is no single explanation for interindividual variability of analgesic therapy with fentanyl TTS. A  comprehensive assessment of the pharmacokinetic and pharmacogenetic factors affecting the efficacy and safety of  analgesic therapy with potent opioids is a tool of a personalized approach for anesthesia in clinical oncology.

1. Schmidt B.L., Hamamoto D.T., Simone D.A., Wilcox G.L. Mechanisms of cancer pain. Mol Interv. 2010; 10 (3): 164–78. doi: 10.1124/mi.10.3.7.

2. Kuip E.J., Zandvliet M.L., Koolen S.L., Mathijssen R.H., van der Rijt C.C. A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patients. Br J Clin. 2017; 83: 294–313. doi: 10.1111/bcp.13129.

3. Novikov G.A. Control of symptoms in palliative medicine. Moscow: GEOTAR-Media, 2013. 248. [in Russian]

4. Pchelintsev M.V. Clinico-pharmacological features and advantages of transdermal application of fentanyl in severe chronic pain. Treating Physician. 2016; 5: 2–7. [in Russian]

5. Bobrova O.P., Zukov R.A., Modestov A.A., Shnayder N.A., Petrova M.M., Pronina E.A. Chronic pain syndrome in oncology: diagnosis and treatment. Krasnoyarsk: Verso. 2017; 128. [in Russian]

6. Syichev D.A., Otdelenov V.A. Inter-drug interactions in internist practice: the view of a clinical pharmacologist. 2014; 12: 18–21. [in Russian]

7. Saari T.I., Laine K., Neuvonen M., Neuvonen P.J., Olkkola K.T. Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl. Eur J Clin Pharmacol. 2008; 64: 25–30. doi:10.1007/s00228-007-0398-x.

8. Kokubun H., Ebinuma K., Matoba M., Takayanagi R., Yamada Y., Yago K. Population pharmacokinetics of transdermal fentanyl in patients with cancer-related pain. J Pain Palliat Care Pharmacother. 2012; 26: 98–104. doi: 10.3109/15360288.2012.679725.

9. Barratt D.T., Bandak B., Klepstad P., Dale O., Kaasa S., Christrup L.L., Tuke J., Somogyi A.A. Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study. Pharmacogenet Genomics. 2014; 24: 185–94. doi: 10.1097/fpc.0000000000000032.

10. Levin T.T., Bakr M.H., Nikolova T. Case report: delirium due to a diltiazem- fentanyl CYP3A4 drug interaction. Gen Hosp Psychiatry. 2010; 32 (6): 648.e9648.e10. doi: 10.1016/j.genhosppsych.2010.08.003.

11. Trobec K., Kerec Kos M., von Haehling S., Springer J., Anker S.D., Lainscak M. Pharmacokinetics of drugs in cachectic patients: a systematic review. PLoS ONE. 2013; 8 (11): e79603.https://doi.org/10.1371/journal.pone.0079603.

12. Grape S., Schug S.A., Lauer S., Schug B.S. Formulations of fentanyl for the management of pain. Drugs. 2010; 70: 57–72. doi: 10.2165/11531740-000000000-00000.

13. Ziesenitz V.C., Konig S.K., Mahlke N., Jantos R., Skopp G., Weiss J., Haefeli W.E., Mikus G. Fentanyl pharmacokinetics is not dependent on hepatic uptake by organic anion-transporting polypeptide 1b1 in human beings. Basic Clin Pharmacol 2013; 113: 43–8. doi: 10.1111/bcpt.12066.

14. Smith M.T., Muralidharan A. Pharmacogenetics of pain and analgesia. Clin Genetics. 2012; 82 (4): 321–330. doi: 10.1111/j.1399-0004.2012.01936.x.

15. Světlík S., Hronová K., Bakhouche H., Matoušková O., Slanař O. Pharmacogenetics of chronic pain and its treatment. Mediators Inflamm. 2013; 13: 1–23. doi: 10.1155/2013/864319.

16. Holzer P. Pharmacology of opioids and their effects on gastrointestinal function. Am J Gastroenterol. 2014; 2: 9–16. doi: 10.1038/ajgsup.2014.4.

17. Takashina Y., Naito T., Mino Y., Yagi T., Ohnishi K., Kawakami J. Impact of CYP3A5 and ABCB1 gene polymorphisms on fentanyl pharmacokinetics and clinical responses in cancer patients undergoing conversion to a transdermal system. Drug Metab Pharmacokinet. 2012; 27: 414–21.

18. Sharom F.J. The P‑glycoprotein multidrug transporter. Essays Biochem. 2011 Sep 7; 50 (1): 161–78. doi: 10.1042/bse0500161.

19. Overholser B.R., Foster D.R. Opioid pharmacokinetic drug – drug interactions. Am J Manag Care. 2011; 17 (11): 276–87.

20. Bobrova O.P., Shnayder N.A., Zyryanov S.K., Modestov A.A. Association of opioid receptors gene OPRM1 polymorphism and phenotypic diversity of chronic pain syndrome of oncological genesis. Medical Genetics. 2017; 16 (6): 3–8. [in Russian]